VFA
PTCT icon

Virtus Fund Advisers’s PTC Therapeutics PTCT Stock Holding History

Virtus Fund Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$363K Buy
+21,752
New +$368K ﹤0.01% 384
2014
Q3 		– Sell
-1,894
Closed -$50K – 1742
2014
Q2 		$50K Buy
+1,894
New +$40.5K ﹤0.01% 1861

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Virtus Fund Advisers's PTCT Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in PTC Therapeutics (PTCT) in Q4 2017: 21,752 shares worth $363K. The stake represents ﹤0.01% of the portfolio and ranks #384 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in PTCT as recently as Q2 2014.

Virtus Fund Advisers first reported a position in PTCT in Q2 2014 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold PTCT as of Q4 2017.

  • Virtus Fund Advisers held 21,752 shares of PTC Therapeutics worth $363K as of Q4 2017.
  • PTC Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • PTC Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #384 holding.
  • Virtus Fund Advisers first reported a position in PTC Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.